A MESSAGE FROM OUR CEO

To each of you who is helping us put an end to cancer, The V Foundation is grateful that you are with us. We know that only by working with many donors, many researchers and many advocates can we truly change the course of cancer and save lives. We are all in this together.

The numbers in this annual report tell one story. They show that our organization is strong due to your enthusiastic support and to great leaders on our Board of Directors. They show that we are gaining strength and momentum. They show that we are making significant grants at institutions around the country for cutting-edge research.

The words and pictures tell another story – a story of generosity and courage and commitment ... of the PEOPLE who are part of The V Foundation, people who are reaching out and giving of themselves to make an important difference, people who read our annual report and respond. Together, we are the many that will keep the numbers strong, keep the momentum going and help save the lives of real people who are diagnosed with cancer now and in years to come – until cancer is no more.

Please drop us a line and let us know what you think about how we’re doing. We’d love to hear from you at info@jimmyv.org.

Best regards,

Chief Executive Officer,
The V Foundation for Cancer Research

OUR MISSION

The V Foundation is a charitable organization dedicated to saving lives by helping to find a cure for cancer. The Foundation seeks to make a difference by generating broad-based support for cancer research and by creating an urgent awareness among all Americans of the importance of the war against cancer. The Foundation performs these dual roles through advocacy, education, fundraising, and philanthropy.
SCIENTIFIC ADVISORY COMMITTEE

MARTIN D. ABELOFF, M.D.  
(In Memoriam)  
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

ROBERT C. BAST, JR., M.D.  
The University of Texas  
MD Anderson Cancer Center

WILLIAM T. BECK, PH.D.  
University of Illinois at Chicago

LISA M. COUSSENS, PH.D.  
Oregon Health and Science University

NANCY E. DAVIDSON, M.D.  
University of Pittsburgh Cancer Institute

H. SHELTON EARP III, M.D.  
UNC Cancer Care

PAUL F. ENGSTROM, M.D.  
Fox Chase Cancer Center

OLIVERA J. FINN, PH.D.  
University of Pittsburgh School of Medicine

RICHARD I. FISHER, M.D.  
Fox Chase Cancer Center

JAMES M. FORD, M.D.  
Stanford University  
School of Medicine

LEVI A. GARRAWAY, M.D., PH.D.  
Dana-Farber Cancer Institute

SUSAN G. HILSENBECK, PH.D.  
Baylor College of Medicine

MICHAEL B. KASTAN, M.D., PH.D.  
Duke Cancer Institute

THEODORE S. LAWRENCE, M.D., PH.D.  
University of Michigan Comprehensive Cancer Center

A. THOMAS LOOK, M.D.  
Dana-Farber Cancer Institute

JOHN D. MINNA, M.D.  
The University of Texas Southwestern Medical Center

JOSEPH O. MOORE, M.D.  
Duke Cancer Institute

WILLIAM G. NELSON, M.D., PH.D.  
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OLUFUNMILAYO OLOPADE, M.D., FACP  
University of Chicago

BRIAN PATRICK O’NEILL, M.D.  
Mayo Clinic Cancer Center

RICHARD J. O’REILLY, M.D.  
Memorial Sloan Kettering Cancer Center

DAVID PIWINICA-WORMS, M.D., PH.D.  
The University of Texas MD Anderson Cancer Center

HELEN PIWINICA-WORMS, PH.D.  
The University of Texas MD Anderson Cancer Center

JEROME RITZ, M.D.  
Dana-Farber Cancer Institute

DAVID E. SCHULLER, M.D.  
The Ohio State University Comprehensive Cancer Center

JONATHAN W. SIMONS, M.D.  
Prostate Cancer Foundation

MARGARET A. TEMPERO, M.D.  
UCSF Comprehensive Cancer Center
BOARD OF DIRECTORS

JIM ALLEGRO
Emeritus Director
Retired Executive Vice President
ESPN, Inc.

JULIE ALLEGRO
General Partner
Allegro Venture Partners

ROBERT C. BAST, JR., M.D.
Vice President for Translational Research
The University of Texas
MD Anderson Cancer Center

GEORGE BODENHEIMER
Retired Executive Chairman
ESPN, Inc.

STEVEN M. BORNSTEIN
Board Chair
The V Foundation
Former President and CEO
NFL Network

GEORGE W. DENNIS III
Retired Senior Partner
Teague Campbell Dennis & Gorham LLP

DAVID FAY
Retired Executive Director
United States Golf Association

ROSA M. GATTI
Retired Senior Vice President, Communications Counsel and Corporate Outreach
ESPN, Inc.

EVAN GOLDBERG
Founder, Chief Technology Officer
Chairman of the Board
NetSuite, Inc.

MARK KING
President
adidas North America

MICHAEL W. KRZYZEWSKI
Head Coach, Men’s Basketball
Duke University

CARL C. LIEBERT III
Chief Operating Officer
USAA Capital Corporation

ROBERT E. LLOYD
Chair Emeritus
The V Foundation

F.J. “JOE” LOUGHREY
Retired Vice President, Vice Chairman
Cummins, Inc.

MICHAEL MACDONALD
Chairman and CEO
Medifast, Inc.

GEOFFREY S. MASON
Senior Production Specialist
ESPN, Inc.

JOSEPH O. MOORE, M.D.
Professor, Hematology and Oncology
Duke Cancer Institute

ROBERT NAKASONE
Retired CEO
Toys ‘R’ Us

DONNA ORENDER
CEO
Orender Unlimited, LLC

KEVIN PLANK
CEO
Under Armour, Inc.
BOARD OF DIRECTORS

LARRY PROBST  
Chairman of the Board  
Electronic Arts  
Chairman  
United States Olympic Committee

HARRY E. RHOADS, JR.  
CEO  
Washington Speakers Bureau

ROBIN ROBERTS  
Co-Anchor  
ABC’s “Good Morning America”

JOHN SAUNDERS  
Sports Commentator  
ESPN, Inc. and ABC Sports

CONSTANCE E. SKIDMORE  
Retired Managing Partner,  
Board Member  
PwC, LLP

JOHN SKIPPER  
President  
ESPN, Inc.

TONY F. SMITH  
Co-Founder  
Managing Director  
Leadership Research Institute

PAMELA VALVANO STRASSER  
Chairwoman  
The V Foundation

STUART A. TAYLOR II  
CEO  
The Taylor Group

NICHOLAS P. VALVANO  
President Emeritus  
The V Foundation

ROBERT VALVANO  
College Basketball Analyst  
Host of “The V Show”  
ESPN, Inc.

LESLEY VISSER  
Sports Commentator  
CBS and HBO

DICK VITALE  
Sports Commentator  
ESPN, Inc. and ABC Sports

R.C. “BUCKY” WATERS  
Retired Vice Chancellor of Development  
Duke University Medical Center  
Sports Commentator  
ESPN, Inc. and Madison Square Garden

ROBERT P. WAYMAN  
Retired Chief Financial Officer  
Executive Vice President  
Hewlett-Packard Company

DERECK WHITTENBURG  
Senior Assistant to the Head Coach  
Director of Player Development  
Men’s Basketball  
North Carolina State University

DAVID W. WILLIAMS  
Retired Senior Vice President  
Whirlpool Corporation

NORBY WILLIAMSON  
Executive Vice President,  
Production, Program Scheduling and  
Development  
ESPN, Inc.

LARRY WOODARD  
President, CEO  
Graham Stanley Advertising
DONOR SPOTLIGHT
Evan and Cindy Goldberg

V Foundation Board Member and NetSuite, Inc. Chief Executive Officer Evan Goldberg and his wife, Cindy, have described our Scientific Advisory Committee as world-class rock stars. With enthusiasm, the couple made a $5 million challenge gift, allowing the committee to fund even more of the best and brightest minds in the fight against cancer. “The SAC is the crown jewel,” said Evan.

“They take a really unique view on cancer because they are experts across all disciplines. They understand the whole playing field of what is working in cancer research, and they can apply that to all types of cancers. I hope my gift allows The V Foundation to continue their unique approach to cancer research and be able to support more innovative potential treatments for cancer.”

RESEARCHER SPOTLIGHT
Benjamin Ebert, M.D.

Dr. Benjamin Ebert, a 2013 V Foundation Translational Grant recipient, and his team at Brigham and Women’s Hospital in Boston have recently published an intriguing study that looked at pre-malignant stages of blood cancers.

Dr. Ebert led one of two research teams that worked independently on decoding DNA in about 30,000 people.

Blood cancers account for approximately 10% of new cancer cases diagnosed in the United States.

The cells that cause cancer must acquire several mutations before cancer actually develops. Dr. Ebert and his team aimed to find individuals who had acquired only the initial mutation but were otherwise healthy. Having the early mutations in the blood does not mean that a person will develop blood cancer, but it does raise the risk. The researchers are hopeful that their findings will lead to screening tests to help identify those at risk of developing blood cancers and ultimately interventions that could prevent the development of blood cancers.
WAYS TO GIVE

Seize the moment. Act now. Join us!

There are many ways to give to The V Foundation for Cancer Research.

1. Go to jimmyv.org/donate to give online.

2. Call The V Foundation to begin your annual or multi-year pledge. Pledges can be paid in a variety of ways, including automatic payments, stocks, checks and donor advised funds.

3. Set up an automatic monthly gift.

4. Wear apparel from the HOMAGE Jimmy V line. Go to jimmyv.org/ShopTheV to purchase.

5. Check with your employer about a matching gifts program.

6. In lieu of gifts for special events, choose to have donations made to The V Foundation.

7. Remember The V Foundation when setting up your will, estate plans or life insurance policies.

2014 GRANTS

V Scholar Grants directly fund young investigators to help them establish their own independent laboratory research projects. Translational Grants facilitate the transition of projects from the laboratory to the patient’s bedside quickly and efficiently. Designated Grants are inspired by particular areas of scientific interest or geographic reach. Recipients are selected based on scientific merit as determined by our Scientific Advisory Committee.

V SCHOLARS

Omar Abdel-Wahab, M.D.
Memorial Sloan Kettering Cancer Center
New York, NY
Understanding and Targeting Spliceosomal Mutations in Leukemia

Mazhar Adli, Ph.D.
University of Virginia Cancer Center
Charlottesville, VA
Epigenetic Engineering to Correct an Aberrantly Regulated Locus in Cancer

Ash A. Alizadeh, M.D., Ph.D.
Stanford Cancer Center
Palo Alto, CA
Non-Invasive Detection and Monitoring of Tumors in Body Fluids

Kara Bernstein, Ph.D.
University of Pittsburgh Cancer Institute
Pittsburgh, PA
Uncovering How Mutations in the RAD51 Paralogues Contribute to Cancer Predisposition and Response to Therapy

Ben Croker, Ph.D.
Boston Children’s Hospital
Boston, MA
Accelerating Hematopoietic Recovery After Chemotherapy and Bone Marrow Transplantation

Emily Dykhuizen, Ph.D.
Purdue University Center for Cancer Research
West Lafayette, IN
The Role of the Bromodomains of PBRM1, a Tumor Suppressive Subunit of the P-BAF Chromatin Remodeling Complex

Angela Fleischman, M.D., Ph.D.
University of California, Irvine
Irvine, CA
Pathogenesis of Calreticulin-Mutated Myeloproliferative Neoplasm

Wenjun Guo, Ph.D.
Albert Einstein College of Medicine
Bronx, NY
Role of Novel Breast Cancer Mutations in Cell Fate Dysregulation and Oncogenesis

Mohit Jain, M.D., Ph.D.
University of California, San Diego
San Diego, CA
Systematic Discovery of Metabolic Vulnerabilities in Cancer

Randall J. Kimple, M.D., Ph.D.
University of Wisconsin Carbone Cancer Center
Madison, WI
Unmasking the Role of HPV in Modulating Tumor Behavior and Therapy Response

Andrew A. Lane, M.D., Ph.D.
Dana-Farber Cancer Institute
Boston, MA
Defining the Contribution of Chromosome X to Gender-Specific Cancer Predisposition

Megan McNerny, M.D., Ph.D.
The University of Chicago Medicine Comprehensive Cancer Center
Chicago, IL
Transcriptional Misregulation in High-Risk Myeloid Neoplasms
2014 GRANTS

V SCHOLARS, CONTINUED

Chad V. Pecot, M.D.
University of North Carolina at Chapel Hill
Lineberger Comprehensive Cancer Center
Chapel Hill, NC
Tumor Angiogenesis Regulation by the miR-200 Family

Karen Sandell Sfanos, Ph.D.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, MD
Alterations in Urinary Tract Microbiome as a Risk Factor for Prostate Cancer

Agnel Sfeir, Ph.D.
New York University
Langone Medical Center
New York, NY
Targeting Polymerase Theta Mediated Double-Strand Break (DSB) Repair in Breast Cancer

Ruoning Wang, Ph.D.
Nationwide Children’s Hospital
Columbus, OH
Metabolic Reprogramming and Modulation of Adaptive Immunity in Tumor Microenvironment
Funded by 2014 Dick Vitale Gala in Memory of Eddie Livingston

John S. Welch, M.D., Ph.D.
Siteman Cancer Center
Washington University
St. Louis, MO
STAG2 Mutations in Leukemia, Hematopoietic Differentiation and Chromatin Structure
Funded by The Hearst Foundation

Kenneth D. Westover, M.D., Ph.D.
The University of Texas
Southwestern Medical Center
Dallas, TX
Development of Irreversible GTPase Active Site Inhibitors for Cancer Therapy
Funded by The Michael and Carole Marks Family

Omer Yilmaz, M.D., Ph.D.
Koch Institute for Integrated Cancer Research at Massachusetts Institute of Technology
Boston, MA
The Mammalian Stem Cell Niche in Cancer
Funded by Delta Chi Fraternity

Weizhou Zhang, Ph.D.
University of Iowa
Holden Comprehensive Cancer Center
Iowa City, IA
Metformin and NLRC4 Inflammasome in Obesity-Associated Cancer Progression

DESIGNATED GRANTS

Parveen Bhatti, Ph.D.
Fred Hutchinson Cancer Center
Seattle, WA
Sleep Disruption and Oxidative DNA Damage Among Shift Workers
Funded by Medifast, Inc.

John Cavanagh, Ph.D.
NC State University
Jimmy V Cancer Therapeutics Training Program
Raleigh, NC
Developing New Cancer Chemotherapeutics: New Screening Protocols
Funded in Partnership with Quad W

Steven DuBois, M.D.
UCSF Benioff Children’s Hospital
San Francisco, CA
Predictors of Response to IGF-R Inhibition in Metastatic Ewing’s Sarcoma
Funded by The Michael and Carole Marks Family

Helene Furberg, M.D., Ph.D.
Vijai Joseph, Ph.D.
Memorial Sloan Kettering Cancer Center
New York, NY
The Role of Germline Genetic Variation in Host Response and Vascular Toxicity from Systemic Chemotherapy for Advanced Urothelial Cancer
Funded by 2014 Wine Celebration Fund-a-Need

Paul J. Hergenrother, Ph.D.
University of Illinois Cancer Center
Chicago, IL
PAC-1 for the Treatment of Breast Cancer
Funded by UNDEFEATED Chicago in Honor of Chicago Blackhawks and Darlene Shaw
Dineo Khabele, M.D.
Vanderbilt University Medical Center
Nashville, TN
*Imaging Ovarian Cancer with Novel Small Molecule Radiotracers of Cyclooxygenase-1*
Funded by The Kay Yow Cancer Fund

Calvin Lee, Ph.D.
All Children’s Hospital
Tampa, FL
*Polycomb Group Protein Control on Micro-RNA Expression in Rhabdomyosarcoma*
Funded by Tampa Bay Lightning Foundation

Hui Li, Ph.D.
University of Virginia
Charlottesville, VA
*Gene Fusions in Rhabdomyosarcoma*
Co-Funded with St. Baldrick’s Foundation

Qing Li, M.D., Ph.D.
University of Michigan
Ann Arbor, MI
*NRAS Signaling in Hematopoietic Stem Cells and Leukemia Stem Cells*

David J. McConkey, Ph.D.
Colin P. N. Dinney, Ph.D.
The University of Texas
MD Anderson Cancer Center
Houston, TX
*Defining the Biological and Clinical Properties of the p53-like/Luminal A Subtype of Bladder Cancer*
Funded by 2014 Wine Celebration

Mo Motamedi, Ph.D.
Massachusetts General Hospital
Boston, MA
*The Role of Sirtuins in Epigenetics and Genomic Stability*

Sabine Mueller, M.D., Ph.D.
UCSF Benioff Children’s Hospital
San Francisco, CA
*Pediatric Diffuse Intrinsic Pontine Gliomas (DIPGs): Developing a Precision Medicine Approach for Children with DIPG*
Funded by 2014 Wine Celebration in Memory of Shunsuke Yamamoto

Hyman B. Muss, M.D.
University of North Carolina at Chapel Hill
Lineberger Comprehensive Cancer Center
Chapel Hill, NC
*Impact of Physical Activity on Biomarkers of Aging and Body Composition Among Breast Cancer Survivors Age 65 and Older*
Funded by The Kay Yow Cancer Fund

Damon Reed, M.D.
Moffitt Cancer Center
Tampa, FL
*Rapid Screening of FDA Approved Chemotherapy Agents to Develop Combinatorial Treatment Regimens for Pediatric Sarcomas*
Funded by 2013 Dick Vitale Gala

Pepper Schedin, Ph.D.
Oregon Health and Science University
Portland, OR
*NSAIDs to Prevent Metastasis of Young Women’s Breast Cancer*
Funded by The Kay Yow Cancer Fund

Judy Villablanca, M.D.
Children’s Hospital of Los Angeles
Los Angeles, CA
*New Approaches to Neuroblastoma Therapy (NANT) Consortium*
Co-Funded with Carousel of Possible Dreams/Friends of Cathryn and 2014 Dick Vitale Gala

Jessie Villanueva, Ph.D.
The Wistar Institute
Philadelphia, PA
*Interrogating the Role of S6K as a Molecular Target in Melanoma*
Co-Funded with The Melanoma Research Alliance
2014 GRANTS

TRANSLATIONAL GRANTS

Scott Antonia, M.D., Ph.D.
Amer Berg, Ph.D.
Dung-Tsa Chen, Ph.D.
Moffitt Cancer Center
Tampa, FL
A Randomized Phase II Study of a Mesothelin Vaccine in Combination with an Anti-PD-1 Monoclonal Antibody and Chemotherapy in Advanced Lung Adenocarcinoma Patients

Nabeel Bardeesy, Ph.D.
Cyril Benes, Ph.D.
Andrew Zhu, M.D., Ph.D.
Massachusetts General Hospital Cancer Center
Boston, MA
Novel Therapies for Intrahepatic Cholangiocarcinoma

Julie E. Bauman, M.D., Ph.D.
Jennifer Grandis, M.D.
Michelle Ozbun, Ph.D.
University of Pittsburgh Cancer Institute
Pittsburgh, PA
Genetic Alterations of PI3KCA Identify Actionable Targets for HPV-Associated Head and Neck Cancer

Selena Chen-Kiang, Ph.D.
Lewis C. Cantley, Ph.D.
John Leonard, M.D.
Peter Martin, M.D.
Maurizio DiLiberto, Ph.D.
New York Presbyterian Hospital
Weill Cornell Medical Center
New York, NY
Cell Cycle Sensitization to PI3K Therapy in Lymphoma

David Cheresh, Ph.D.
Razelle Kurzrock, M.D.
Karen Messer, Ph.D.
Hatim Husain, M.D.
University of California, San Diego
Moores Cancer Center
San Diego, CA
Integrin avB3 as a CTC Biomarker and Therapeutic Target for Erlotinib-Resistant Lung Cancer

Michael Deininger, M.D., Ph.D.
Thomas O’Hare, Ph.D.
University of Utah
Huntsman Cancer Institute
Salt Lake City, UT
Pathway-Informed Targeted Therapy in Chronic Myelomonocytic Leukemia

Andrew Feinberg, M.D., MPH
Philip Cole, M.D., Ph.D.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, MD
Epigenetic Detection and Chemoprevention of Skin Cancer

Michael C. Heinrich, M.D.
Oregon Health and Science University
Portland, OR
Combination Therapy for KIT-Mutant Cancer: An Integrated Systems Biology Approach

Darrell J. Irvine, Ph.D.
Koch Institute for Integrated Cancer Research at Massachusetts Institute of Technology
Boston, MA
Lymph Node Targeted Patient-Specific Vaccines

Michael B. Major, Ph.D.
D. Neil Hayes, M.D., MPH
Gary Johnson, Ph.D.
University of North Carolina at Chapel Hill
Lineberger Comprehensive Cancer Center
Chapel Hill, NC
Global Kinase Activity Profiling for Improved Patient Stratification and Response to Targeted Therapy
TOPK (T-LAK Cell-Originated Protein Kinase): A New Target for FLT3 Mutated AML

David J. Tweardy, M.D.
Michael T. Lewis, Ph.D.
Mothaffar F. Rimawi, M.D.
Baylor College of Medicine
Dan L. Duncan Cancer Center
Houston, TX
Oral Small Molecular Stat3 Inhibitor to Treat Breast Cancer
<table>
<thead>
<tr>
<th>Cancer Type</th>
<th>Grants</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>General/Other</td>
<td>195</td>
<td>$27.3 million</td>
</tr>
<tr>
<td>Leukemia/Lymphoma</td>
<td>85</td>
<td>$24.2 million</td>
</tr>
<tr>
<td>Pediatric</td>
<td>55</td>
<td>$15 million</td>
</tr>
<tr>
<td>Breast</td>
<td>62</td>
<td>$13.3 million</td>
</tr>
<tr>
<td>Lung</td>
<td>42</td>
<td>$13 million</td>
</tr>
<tr>
<td>Melanoma</td>
<td>24</td>
<td>$7.9 million</td>
</tr>
<tr>
<td>Pancreatic</td>
<td>15</td>
<td>$5.5 million</td>
</tr>
<tr>
<td>GI</td>
<td>31</td>
<td>$5.4 million</td>
</tr>
<tr>
<td>Prostate</td>
<td>26</td>
<td>$4.8 million</td>
</tr>
<tr>
<td>Brain</td>
<td>13</td>
<td>$3.7 million</td>
</tr>
<tr>
<td>Cervical/Ovarian/Gynecological</td>
<td>11</td>
<td>$3.2 million</td>
</tr>
<tr>
<td>Renal</td>
<td>9</td>
<td>$3.1 million</td>
</tr>
<tr>
<td>Head and Neck</td>
<td>8</td>
<td>$2.2 million</td>
</tr>
<tr>
<td>Colon</td>
<td>5</td>
<td>$1.2 million</td>
</tr>
<tr>
<td>Ewing’s Sarcoma</td>
<td>5</td>
<td>$800,000</td>
</tr>
<tr>
<td>Myeloma</td>
<td>2</td>
<td>$100,000</td>
</tr>
</tbody>
</table>
# STATEMENT OF FINANCIAL POSITION

SEPTEMBER 30, 2014

## ASSETS

### CURRENT ASSETS
- Cash and Cash Equivalents: $14,447,383
- Accounts Receivable: $92,800
- Promises to Give, Net: $3,787,177
- Grants Receivable: $1,450,000
- Prepaid Expenses: $24,694

**TOTAL CURRENT ASSETS**: $19,802,054

### PROPERTY AND EQUIPMENT, NET

TOTAL OTHER ASSETS: $35,628,347

### OTHER ASSETS
- Investments: $26,895,259
- Promises to Give, Net: $4,808,220
- Grants Receivable, Net: $3,874,868
- Intangible Assets: $50,000

**TOTAL ASSETS**: $55,466,949
STATEMENT OF FINANCIAL POSITION

LIABILITIES AND NET ASSETS

CURRENT LIABILITIES
Accounts Payable and Accrued Expenses $95,698
Accrued Payroll and Related Liabilities $58,456
Deferred Rent $10,000
Deferred Revenue $12,500
Grants Payable $13,402,500

TOTAL CURRENT LIABILITIES $13,579,154

LONG-TERM LIABILITIES
Deferred Rent $30,350
Grants Payable, Net $10,544,962

TOTAL LIABILITIES $24,154,466

NET ASSETS
Unrestricted
Board Designated $8,428,485
Undesignated $(2,035,128)

$6,393,357

Temporarily Restricted $12,745,909
Permanently Restricted $12,173,217

TOTAL NET ASSETS $31,312,483

TOTAL LIABILITIES AND NET ASSETS $55,466,949
# STATEMENT OF ACTIVITIES AND CHANGES IN NET ASSETS

For the year ended September 30, 2014

## SUPPORT AND REVENUE

<table>
<thead>
<tr>
<th>Category</th>
<th>Unrestricted</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions and Gifts</td>
<td>$13,087,046</td>
</tr>
<tr>
<td>Special Events</td>
<td></td>
</tr>
<tr>
<td>Contributions</td>
<td>$1,866,341</td>
</tr>
<tr>
<td>Event Income</td>
<td>$274,225</td>
</tr>
<tr>
<td>Less - Costs of Direct Benefits to Donors</td>
<td>($760,150)</td>
</tr>
<tr>
<td>Net Revenues from Special Events</td>
<td>$1,380,416</td>
</tr>
<tr>
<td>License Income</td>
<td>$4,191</td>
</tr>
<tr>
<td>Investment Income, Net of Fees</td>
<td>$139,171</td>
</tr>
<tr>
<td>Unrealized Gain on Investments</td>
<td>$376,453</td>
</tr>
<tr>
<td>Realized Gain on Investments</td>
<td>$273,752</td>
</tr>
<tr>
<td>Net Assets Released from Restrictions</td>
<td></td>
</tr>
<tr>
<td>TOTAL SUPPORT AND REVENUE</td>
<td>$15,261,029</td>
</tr>
</tbody>
</table>

## EXPENSES

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program Services</td>
<td>$16,714,322</td>
</tr>
<tr>
<td>Supporting Services</td>
<td></td>
</tr>
<tr>
<td>Management and General</td>
<td>$801,513</td>
</tr>
<tr>
<td>Fundraising Expenses</td>
<td>$1,304,498</td>
</tr>
<tr>
<td>Total Support Services</td>
<td>$2,106,011</td>
</tr>
<tr>
<td>SUBTOTAL EXPENSES</td>
<td>$18,820,333</td>
</tr>
<tr>
<td>Loss from Bad Debts</td>
<td>--</td>
</tr>
<tr>
<td>TOTAL EXPENSES</td>
<td>$18,820,333</td>
</tr>
</tbody>
</table>

## CHANGES IN NET ASSETS

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>NET ASSETS - BEGINNING OF YEAR</td>
<td>$1,927,311</td>
</tr>
<tr>
<td>NET ASSETS - END OF YEAR</td>
<td>$6,393,357</td>
</tr>
</tbody>
</table>
STATEMENT OF ACTIVITIES AND CHANGES IN NET ASSETS

<table>
<thead>
<tr>
<th>Temporarily Restricted</th>
<th>Permanently Restricted</th>
<th>2014 Totals</th>
</tr>
</thead>
<tbody>
<tr>
<td>$15,221,538</td>
<td>$32,961</td>
<td>$28,341,545</td>
</tr>
<tr>
<td>--</td>
<td>--</td>
<td>$1,866,341</td>
</tr>
<tr>
<td>--</td>
<td>--</td>
<td>$274,225</td>
</tr>
<tr>
<td>--</td>
<td>--</td>
<td>($760,150)</td>
</tr>
<tr>
<td>$308,788</td>
<td>--</td>
<td>$4,191</td>
</tr>
<tr>
<td>$887,228</td>
<td>--</td>
<td>$1,263,681</td>
</tr>
<tr>
<td>$645,179</td>
<td>--</td>
<td>$918,931</td>
</tr>
<tr>
<td>$17,062,733</td>
<td>$32,961</td>
<td>$32,356,723</td>
</tr>
<tr>
<td>($8,025,350)</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>$9,037,383</td>
<td>$32,961</td>
<td>$32,356,723</td>
</tr>
<tr>
<td>--</td>
<td>--</td>
<td>$16,714,322</td>
</tr>
<tr>
<td>--</td>
<td>--</td>
<td>$801,513</td>
</tr>
<tr>
<td>--</td>
<td>--</td>
<td>$1,304,498</td>
</tr>
<tr>
<td>--</td>
<td>--</td>
<td>$2,106,011</td>
</tr>
<tr>
<td>--</td>
<td>--</td>
<td>$18,820,333</td>
</tr>
<tr>
<td>$224,050</td>
<td>($23,245)</td>
<td>$200,805</td>
</tr>
<tr>
<td>$224,050</td>
<td>($23,245)</td>
<td>$19,021,138</td>
</tr>
<tr>
<td>$8,813,333</td>
<td>$56,206</td>
<td>$13,335,585</td>
</tr>
<tr>
<td>$3,932,576</td>
<td>$12,117,011</td>
<td>$17,976,898</td>
</tr>
<tr>
<td>$12,745,909</td>
<td>$12,173,217</td>
<td>$31,312,483</td>
</tr>
</tbody>
</table>

(The V Foundation for Cancer Research Annual Report 2014)
DONOR SPOTLIGHT
Kevin and Ouida Chorniak

Kevin and Ouida Chorniak have been V Foundation supporters for several years. While their ultimate goal is an end to cancer, they know it will take time.

“Of course, the big goal is to end cancer and to make progress to get there,” explained Kevin. “It won’t be overnight, but [the Foundation] is making meaningful progress toward the end goal. We’ve been touched by a lot of people in our lives who have had cancer. Some have recovered, and some did not. The more we’ve learned, we’ve become big fans of the work you’re doing and the way you’re doing it.”

Ouida agreed. “I’ve always wanted to support this work,” she said. “Cancer has taken a lot of people that we love. I’m so passionate about your organization. I love that it is funded the way it is. I love what it stands for.”

PARTNER SPOTLIGHT
Sony PlayStation HEROES

In a joint effort with ESPN, Sony PlayStation offered gamers an opportunity to be heroes in the virtual world AND in the real world with the launch of their new PlayStation program. Sony provided $100,000 to The V Foundation to kick off the campaign.

The HEROES app launched in February 2015. Consumers were entered for a chance to play PlayStation games with celebrities through the purchase of digital items. For each dollar spent, participants received one entry into the drawing, and 90% of the purchase price of items went to charity. The V Foundation was paired with Los Angeles Dodgers baseball star Yasiel Puig.

“I am very excited and honored to be a part of Playstation HEROES and to be a part of The V Foundation and their efforts to search for a cure for cancer,” said Puig. “I would love a world where people can live longer, where people don’t have these types of diseases, where kids can live longer and accomplish their wishes and dreams, where we don’t lose good people.”
THANK YOU to all of our generous donors whose support allows us to continue to advance our mission. We celebrate you and our united passion for eliminating cancer. Our appreciation and gratitude extend to so many who played a vital role in 2014’s successes.

The V Foundation’s mission would not be possible without individuals and families who donate to make fighting cancer an urgent and important priority. THANK YOU!

Our corporate partners share our vision that a world without cancer is possible; their commitment is invaluable in helping us achieve that vision. THANK YOU for setting a high example in leadership and philanthropic values.

To the employees who request matching funds from their employers, THANK YOU for taking the extra step and signing the additional paperwork -- all to increase your donation and your impact.

The V Foundation’s events and public awareness campaigns are successful in large part because of our supporters and those who participate. THANK YOU for providing goods and services that resulted in increased awareness and cost-saving initiatives.

To endowment donors, THANK YOU for believing in the work being accomplished and investing in the future to continue a stream of resources that fund the best, most innovative research.

Our sincerest recognition and gratitude to all who give generously to The V Foundation’s mission to never give up on fighting cancer.